Carly Helfand

Biography for Carly Helfand

Carly Helfand, News Editor

Carly Helfand is a news editor with Fierce's life sciences group, writing for FiercePharma, FiercePharmaMarketing and FierceVaccines. Carly got her start covering pharma while earning her master’s at Northwestern University’s Medill School of Journalism, where she concentrated in business reporting. She has completed journalism projects on four continents, and her work has appeared in various outlets such as The Boston Globe, The Washington Post’s “Wonkblog” and Cape Town’s Weekend Argus. Carly prefers watching pro hockey to nearly everything. She also plays the Irish fiddle. You can contact her at chelfand@fiercemarkets.com and follow her on Twitter at @CarlyHFierce.

Articles by Carly Helfand

Trump's Twitter tirade blames vaccines for autism increase

Donald Trump has once again pushed a debunked link between vaccines and autism, this time weighing in after the Centers for Disease Control and Prevention published a report indicating that the number of children in America with the disorder has jumped from 1 in 88 two years ago to 1 in 68.

Vaccines sale figures into Baxter's breakup plans

The same day Baxter announced it would be dividing into separate biopharma and med tech companies come 2015, it revealed plans to sell its vaccines unit as part of the larger breakup.

'Breakthrough' nod for Pfizer MenB candidate sets up showdown with Bexsero

Pfizer's approval pathway for its meningococcal B vaccine just got shorter. On Thursday, the FDA designated the candidate, dubbed rLP2086, as a breakthrough therapy, which will speed its trip through the regulatory process--and put it in a head-to-head battle with Novartis' Bexsero.

Northwest Bio, NewLink proceed with cancer vax trials to mixed reviews

A pair of biotechs will proceed with cancer vaccine studies thanks to recent recommendations from data-monitoring committees. Their announcements drew mixed results from investors, with Northwest Biotherapeutics' shares soaring and NewLink Genetics' sinking. But as they forge ahead, both companies will have to shake off the looming specters of failed cancer vaccine trials past.

Sanofi makes inactive polio vaccine available to poor countries for $1 a dose

Back in November, the GAVI Alliance added inactivated poliovirus vaccines to the list of products it makes available in the world's poorest countries. Now UNICEF is adding its backing, striking a deal with Sanofi to supply the vaccine to GAVI-supported countries for as little as $1 per dose.

  • « first
  • ‹ previous
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • 18
  • 19
  • 20